← Back to Search

MoveMend Health for Transplant Patients

N/A

Recruiting

Led By Steve Vanlew

Research Sponsored by NYU Langone Health

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Orientation Log > 25

Status post kidney or liver transplant this admission

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to month 6 post-operation

Awards & highlights

No Placebo-Only Group

Summary

This trial aims to see if a new software program, MoveMend Health, can be helpful for patients who have had liver and kidney transplants. Researchers will look at how many patients join the program

Who is the study for?

This trial is for English-speaking patients who have recently undergone a kidney or liver transplant and are in the hospital. They must be mentally oriented, not delirious, and have a doctor's order for occupational therapy.

What is being tested?

The study is testing MoveMend Health software as an extra activity during regular occupational therapy sessions for patients recovering from liver or kidney transplants to see if it's doable and helpful.

What are the potential side effects?

Since this trial involves exercise through a software program, potential side effects may include muscle soreness or strain. The safety of the program will also be monitored throughout the study.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My mental orientation score is above 25.

Select...

I have had a kidney or liver transplant during this hospital stay.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to month 6 post-operation

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to month 6 post-operation

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to month 6 post-operation for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Number of Adverse Events

Percentage of Participants who Adhere to Intervention

Percentage of Participants who Complete Exercise Program

+1 more

Secondary study objectives

Change in Activity Measure for Post-Acute Care (AMPAC) Score

Change in EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire Index Score

Change in Grip Strength

+1 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Patients Hospitalized following Kidney or Liver TransplantExperimental Treatment1 Intervention

Patients in the study will be introduced to the exercise software program and provided with a demonstration. Measurements will be taken at baseline (post-operation) and at the final study visit. Participants will remain in the study until the end of their hospital stay, typically no longer than 6 months post-operation.

0 / 2Eligibility criteria met